Elizabeth M. Poole

Elizabeth M. Poole

Auto-generated profile, based on publicly available information

Elizabeth M. Poole


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2013 in American Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
EPElizabeth M. Poole
Elizabeth M. Poole
ILI-Min Lee
I-Min Lee
PRPaul M. Ridker
Paul M. Ridker
JBJulie E. Buring
Julie E. Buring
SHSusan E. Hankinson
Susan E. Hankinson
STShelley S Tworoger
Shelley S Tworoger
Chronic inflammation may play a role in ovarian carcinogenesis. We examined associations between 3 plasma biomarkers of inflammation—C-reactive protein (CRP), interleukin 6, and tumor necrosis factor α receptor 2—and risk of invasive epithelial ovarian cancer in prospectively collected samples from the Nurses' Health Study (NHS; 1989–2010), Nurses’ Health Study II (NHS II; 1996–2009), and the Women's Health Study (WHS; 1992–2011) and performed a meta-analysis including data from previous publications. Associations with ovarian cancer risk were calculated using logistic regression (NHS/NHS II; n = 217 cases) or Cox proportional hazards regression (WHS; n = 159 cases). Study-specific results were combined using random-effects meta-analysis. In the NHS/NHS II and WHS, we observed a 53% increased risk of invasive ovarian cancer when comparing women in the fourth quartile of CRP with women in the first quartile (95% confidence interval (CI): 1.05, 2.23). A CRP level of >10 mg/L versus a level of ≤1 mg/L was associated with a 2.16-fold increased risk (95% CI: 1.23, 3.78). In a meta-analysis of published studies, women in the third tertile of CRP had a 35% increased risk (95% CI: 1.10, 1.67) compared with women in the first tertile. There were no significant associations between interleukin 6 or tumor necrosis factor α receptor 2 and risk in the NHS/NHS II. Our results support the hypothesis that higher levels of circulating CRP are associated with increased risk of ovarian cancer, indicating that the role of inflammation in ovarian cancer requires further elucidation.

9 August 2011 in American Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
EPElizabeth M. Poole
Elizabeth M. Poole
STShelley S Tworoger
Shelley S Tworoger
SHSusan E. Hankinson
Susan E. Hankinson
Eva SchernhammerEva Schernhammer
Eva Schernhammer
MPMichael N. Pollak
Michael N. Pollak
HBHeather J. Baer
Heather J. Baer
Body size in early life has been associated with breast cancer risk. This may be partly mediated through the insulin-like growth factor (IGF) pathway. The authors assessed whether birth weight, body fatness at ages 5 and 10 years, and body mass index (BMI; weight (kg)/height (m)2) at age 18 years were associated with plasma concentrations of insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 3 in 6,520 women aged 32–70 years at blood draw from the Nurses’ Health Study (1990–2006) and Nurses’ Health Study II (1997–2005). Birth weight, body fatness in childhood, and BMI at age 18 years were inversely associated with adult IGF-1 levels. For example, IGF-1 levels were 11.9% lower in women who reported being heaviest at age 10 years than in those who were leanest at age 10 (P-trend < 0.0001). Further, women who reported their birth weight as ≥10 pounds (≥4.5 kg) (vs. <5.5 pounds (<2.5 kg)) had 7.9% lower IGF-1 levels (P-trend = 0.002). Women whose BMI at age 18 years was ≥30 (vs. <20) had 14.1% lower IGF-1 levels (P-trend < 0.0001). Similar inverse associations were observed for insulin-like growth factor binding protein 3. These observations did not vary by adult BMI or menopausal status at blood draw. These findings suggest that altered IGF-1 levels in adulthood may be a mechanism through which early-life body size influences subsequent breast cancer risk.

1 March 2013 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
EPElizabeth M. Poole
Elizabeth M. Poole
MMMelissa A. Merritt
Melissa A. Merritt
SJSusan J. Jordan
Susan J. Jordan
HYHannah P. Yang
Hannah P. Yang
SHSusan E. Hankinson
Susan E. Hankinson
STShelley S Tworoger
Shelley S Tworoger
Background: Approximately half of epithelial ovarian cancers are fatal within 3 years; however, roughly 35% of women survive for at least 10 years. In the Nurses' Health Study, New England Case-Control Study, Australian Ovarian Cancer Study, and NIH-AARP Diet and Health Study, we investigated potential differences in the associations with ovarian cancer risk factors by tumor aggressiveness, defined on the basis of time from diagnosis until death. Methods: We calculated relative risks (RR) and 95% confidence intervals (CI) for associations of known or suspected ovarian cancer risk factors with rapidly fatal (death within 3 years of diagnosis) and less aggressive tumors (all others) using Cox proportional hazards competing risks analysis (NHS and AARP) or polytomous logistic regression (NECC, AOCS). Results were combined using random effects meta-analysis. Results: Increasing age was associated with greater risk of rapidly fatal versus less aggressive disease (RR, 5-year increase: 1.39; 95% CI, 1.29–1.49 vs. RR, 1.09; 95% CI, 1.03–1.16, respectively; Pdiff < 0.0001). Oral contraceptive use was associated with a greater decreased risk of rapidly fatal (RR, 5-year increase: 0.69; 95% CI, 0.58–0.82) versus less aggressive disease (RR, 0.81; 95% CI, 0.74–0.89; Pdiff, 0.002). Conversely, increasing parity was associated only with less aggressive disease (RR per child, 0.87; 95% CI, 0.81–0.93). Conclusion: In this analysis of 4,342 cases, there were clear differences in risk factors for rapidly fatal versus less aggressive ovarian tumors. Impact: Differences in risk factor associations by tumor aggressiveness suggests the developmental pathways through which the tumors develop and may be important for developing primary preventive strategies for the most aggressive cancers. Cancer Epidemiol Biomarkers Prev; 22(3); 429–36. ©2013 AACR.

10 May 2013 in Breast Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
EPElizabeth M. Poole
Elizabeth M. Poole
XSXiaoOu Shu
XiaoOu Shu
BCBette J. Caan
Bette J. Caan
SFShirley W. Flatt
Shirley W. Flatt
MHMichelle D. Holmes
Michelle D. Holmes
WCWendy Y. Chen
Wendy Y. Chen
Vitamin supplement use after breast cancer diagnosis is common, but little is known about long-term effects on recurrence and survival. We examined postdiagnosis supplement use and risk of death or recurrence in the After Breast Cancer Pooling Project, a consortium of four cohorts of 12,019 breast cancer survivors from the United States and China. Post-treatment supplement use (vitamins A, B, C, D, E, and multivitamins) was assessed 1–5 years postdiagnosis. Associations with risk of recurrence, breast cancer-specific mortality, or total mortality were analyzed in Cox proportional hazards models separately by cohort. Individual cohort results were combined using random effects meta-analysis. Interactions with smoking, treatment, and hormonal status were examined. In multivariate models, vitamin E was associated with a decreased risk of recurrence (RR: 0.88; 95 % CI 0.79–0.99), and vitamin C with decreased risk of death (RR: 0.81; 95 % CI 0.72–0.92). However, when supplements were mutually adjusted, all associations were attenuated. There were no statistically significant associations with breast cancer mortality. The use of antioxidant supplements (multivitamins, vitamin C, or E) was not associated with recurrence, but was associated with a 16 % decreased risk of death (95 % CI 0.72–0.99). In addition, vitamin D was associated with decreased risk of recurrence among ER positive, but not ER negative tumors (p-interaction = 0.01). In this large consortium of breast cancer survivors, post-treatment use of vitamin supplements was not associated with increased risk of recurrence or death. Post-treatment use of antioxidant supplements was associated with improved survival, but the associations with individual supplement were difficult to determine. Stratification by ER status and considering antioxidants as a group may be more clinically relevant when evaluating associations with cancer risk and mortality.

15 March 2017 in Cancer Causes & Control
Verified
Journal Article
Closed access
PDF file
EPElizabeth M. Poole
Elizabeth M. Poole
WLWayne T. Lin
Wayne T. Lin
MKMarina Kvaskoff
Marina Kvaskoff
IVImmaculata De Vivo
Immaculata De Vivo
KTKathryn L. Terry
Kathryn L. Terry
SMStacey A. Missmer
Stacey A. Missmer

8 January 2016 in Psycho-Oncology
Verified
Journal Article
Open access
PDF file
CKCandyce H. Kroenke
Candyce H. Kroenke
YMYvonne L. Michael
Yvonne L. Michael
XSXiao‐Ou Shu
Xiao‐Ou Shu
EPElizabeth M. Poole
Elizabeth M. Poole
MKMarilyn L. Kwan
Marilyn L. Kwan
WCWendy Y. Chen
Wendy Y. Chen
Objective: Larger social networks have been associated with better breast cancer survival. To investigate potential mediators, we evaluated associations of social network size and diversity with lifestyle and treatment factors associated with prognosis.Methods: We included 9331 women from the After Breast Cancer Pooling Project who provided data on social networks within approximately two years following diagnosis. A social network index was derived from information about the presence of a spouse or intimate partner, religious ties, community participation, friendship ties, and numbers of living relatives. Diversity was assessed as variety of ties, independent of size. We used logistic regression to evaluate associations with outcomes and evaluated whether effect estimates differed using meta‐analytic techniques.Results: Associations were similar across cohorts though analyses of smoking and alcohol included US cohorts only because of low prevalence of these behaviors in the Shanghai cohort. Socially isolated women were more likely to be obese (OR = 1.21, 95% CI:1.03–1.42), have low physical activity (<10 MET‐hours/week, OR = 1.55, 95% CI:1.36–1.78), be current smokers (OR = 2.77, 95% CI:2.09‐3.68), and have high alcohol intake (≥15 g/d, OR = 1.23, 95% CI:1.00–1.51), compared with socially integrated women. Among node positive cases from three cohorts, socially isolated women were more likely not to receive chemotherapy (OR = 2.10, 95% CI:1.30–3.39); associations differed in a fourth cohort. Other associations (nonsignificant) were consistent with less intensive treatment in socially isolated women. Low social network diversity was independently associated with more adverse lifestyle, but not clinical, factors.Conclusions: Small, less diverse social networks measured post‐diagnosis were associated with more adverse lifestyle factors and less intensive cancer treatment. Copyright © 2016 John Wiley & Sons, Ltd.